<?xml version='1.0' encoding='utf-8'?>
<document id="27504016"><sentence text="In Vitro and In Vivo Drug-Drug Interaction Studies to Assess the Effect of Abiraterone Acetate, Abiraterone, and Metabolites of Abiraterone on CYP2C8 Activity."><entity charOffset="75-94" id="DDI-PubMed.27504016.s1.e0" text="Abiraterone Acetate" /><entity charOffset="96-107" id="DDI-PubMed.27504016.s1.e1" text="Abiraterone" /><entity charOffset="128-139" id="DDI-PubMed.27504016.s1.e2" text="Abiraterone" /><pair ddi="false" e1="DDI-PubMed.27504016.s1.e0" e2="DDI-PubMed.27504016.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27504016.s1.e0" e2="DDI-PubMed.27504016.s1.e1" /><pair ddi="false" e1="DDI-PubMed.27504016.s1.e0" e2="DDI-PubMed.27504016.s1.e2" /><pair ddi="false" e1="DDI-PubMed.27504016.s1.e1" e2="DDI-PubMed.27504016.s1.e1" /><pair ddi="false" e1="DDI-PubMed.27504016.s1.e1" e2="DDI-PubMed.27504016.s1.e2" /></sentence><sentence text="Abiraterone acetate, the prodrug of the cytochrome P450 C17 inhibitor abiraterone, plus prednisone is approved for treatment of metastatic castration-resistant prostate cancer"><entity charOffset="0-19" id="DDI-PubMed.27504016.s2.e0" text="Abiraterone acetate" /><entity charOffset="70-81" id="DDI-PubMed.27504016.s2.e1" text="abiraterone" /><entity charOffset="88-98" id="DDI-PubMed.27504016.s2.e2" text="prednisone" /><pair ddi="false" e1="DDI-PubMed.27504016.s2.e0" e2="DDI-PubMed.27504016.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27504016.s2.e0" e2="DDI-PubMed.27504016.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27504016.s2.e0" e2="DDI-PubMed.27504016.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27504016.s2.e1" e2="DDI-PubMed.27504016.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27504016.s2.e1" e2="DDI-PubMed.27504016.s2.e2" /></sentence><sentence text=" We explored whether abiraterone interacts with drugs metabolized by CYP2C8, an enzyme responsible for the metabolism of many drugs"><entity charOffset="21-32" id="DDI-PubMed.27504016.s3.e0" text="abiraterone" /></sentence><sentence text=" Abiraterone acetate and abiraterone and its major metabolites, abiraterone sulfate and abiraterone sulfate N-oxide, inhibited CYP2C8 in human liver microsomes, with IC50 values near or below the peak total concentrations observed in patients with metastatic castration-resistant prostate cancer (IC50 values: 1"><entity charOffset="1-20" id="DDI-PubMed.27504016.s4.e0" text="Abiraterone acetate" /><entity charOffset="25-36" id="DDI-PubMed.27504016.s4.e1" text="abiraterone" /><entity charOffset="64-83" id="DDI-PubMed.27504016.s4.e2" text="abiraterone sulfate" /><entity charOffset="88-115" id="DDI-PubMed.27504016.s4.e3" text="abiraterone sulfate N-oxide" /><pair ddi="false" e1="DDI-PubMed.27504016.s4.e0" e2="DDI-PubMed.27504016.s4.e0" /><pair ddi="false" e1="DDI-PubMed.27504016.s4.e0" e2="DDI-PubMed.27504016.s4.e1" /><pair ddi="false" e1="DDI-PubMed.27504016.s4.e0" e2="DDI-PubMed.27504016.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27504016.s4.e0" e2="DDI-PubMed.27504016.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27504016.s4.e1" e2="DDI-PubMed.27504016.s4.e1" /><pair ddi="false" e1="DDI-PubMed.27504016.s4.e1" e2="DDI-PubMed.27504016.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27504016.s4.e1" e2="DDI-PubMed.27504016.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27504016.s4.e2" e2="DDI-PubMed.27504016.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27504016.s4.e2" e2="DDI-PubMed.27504016.s4.e3" /></sentence><sentence text="3-3" /><sentence text="0 µM, 1" /><sentence text="6-2" /><sentence text="9 µM, 0" /><sentence text="044-0" /><sentence text="15 µM, and 5" /><sentence text="4-5" /><sentence text="9 µM, respectively)" /><sentence text=" CYP2C8 inhibition was reversible and time-independent" /><sentence text=" To explore the clinical relevance of the in vitro data, an open-label, single-center study was conducted comprising 16 healthy male subjects who received a single 15-mg dose of the CYP2C8 substrate pioglitazone on day 1 and again 1 hour after the administration of abiraterone acetate 1000 mg on day 8"><entity charOffset="199-211" id="DDI-PubMed.27504016.s14.e0" text="pioglitazone" /><entity charOffset="266-285" id="DDI-PubMed.27504016.s14.e1" text="abiraterone acetate" /><pair ddi="false" e1="DDI-PubMed.27504016.s14.e0" e2="DDI-PubMed.27504016.s14.e0" /><pair ddi="false" e1="DDI-PubMed.27504016.s14.e0" e2="DDI-PubMed.27504016.s14.e1" /></sentence><sentence text=" Plasma concentrations of pioglitazone, its active M-III (keto derivative) and M-IV (hydroxyl derivative) metabolites, and abiraterone were determined for up to 72 hours after each dose"><entity charOffset="26-38" id="DDI-PubMed.27504016.s15.e0" text="pioglitazone" /><entity charOffset="51-56" id="DDI-PubMed.27504016.s15.e1" text="M-III" /><entity charOffset="58-62" id="DDI-PubMed.27504016.s15.e2" text="keto" /><entity charOffset="79-83" id="DDI-PubMed.27504016.s15.e3" text="M-IV" /><entity charOffset="85-93" id="DDI-PubMed.27504016.s15.e4" text="hydroxyl" /><entity charOffset="123-134" id="DDI-PubMed.27504016.s15.e5" text="abiraterone" /><pair ddi="false" e1="DDI-PubMed.27504016.s15.e0" e2="DDI-PubMed.27504016.s15.e0" /><pair ddi="false" e1="DDI-PubMed.27504016.s15.e0" e2="DDI-PubMed.27504016.s15.e1" /><pair ddi="false" e1="DDI-PubMed.27504016.s15.e0" e2="DDI-PubMed.27504016.s15.e2" /><pair ddi="false" e1="DDI-PubMed.27504016.s15.e0" e2="DDI-PubMed.27504016.s15.e3" /><pair ddi="false" e1="DDI-PubMed.27504016.s15.e0" e2="DDI-PubMed.27504016.s15.e4" /><pair ddi="false" e1="DDI-PubMed.27504016.s15.e0" e2="DDI-PubMed.27504016.s15.e5" /><pair ddi="false" e1="DDI-PubMed.27504016.s15.e1" e2="DDI-PubMed.27504016.s15.e1" /><pair ddi="false" e1="DDI-PubMed.27504016.s15.e1" e2="DDI-PubMed.27504016.s15.e2" /><pair ddi="false" e1="DDI-PubMed.27504016.s15.e1" e2="DDI-PubMed.27504016.s15.e3" /><pair ddi="false" e1="DDI-PubMed.27504016.s15.e1" e2="DDI-PubMed.27504016.s15.e4" /><pair ddi="false" e1="DDI-PubMed.27504016.s15.e1" e2="DDI-PubMed.27504016.s15.e5" /><pair ddi="false" e1="DDI-PubMed.27504016.s15.e2" e2="DDI-PubMed.27504016.s15.e2" /><pair ddi="false" e1="DDI-PubMed.27504016.s15.e2" e2="DDI-PubMed.27504016.s15.e3" /><pair ddi="false" e1="DDI-PubMed.27504016.s15.e2" e2="DDI-PubMed.27504016.s15.e4" /><pair ddi="false" e1="DDI-PubMed.27504016.s15.e2" e2="DDI-PubMed.27504016.s15.e5" /><pair ddi="false" e1="DDI-PubMed.27504016.s15.e3" e2="DDI-PubMed.27504016.s15.e3" /><pair ddi="false" e1="DDI-PubMed.27504016.s15.e3" e2="DDI-PubMed.27504016.s15.e4" /><pair ddi="false" e1="DDI-PubMed.27504016.s15.e3" e2="DDI-PubMed.27504016.s15.e5" /><pair ddi="false" e1="DDI-PubMed.27504016.s15.e4" e2="DDI-PubMed.27504016.s15.e4" /><pair ddi="false" e1="DDI-PubMed.27504016.s15.e4" e2="DDI-PubMed.27504016.s15.e5" /></sentence><sentence text=" Abiraterone acetate increased exposure to pioglitazone; the geometric mean ratio (day 8/day 1) was 125 [90% confidence interval (CI), 99"><entity charOffset="1-20" id="DDI-PubMed.27504016.s16.e0" text="Abiraterone acetate" /><entity charOffset="43-55" id="DDI-PubMed.27504016.s16.e1" text="pioglitazone" /><pair ddi="false" e1="DDI-PubMed.27504016.s16.e0" e2="DDI-PubMed.27504016.s16.e0" /><pair ddi="false" e1="DDI-PubMed.27504016.s16.e0" e2="DDI-PubMed.27504016.s16.e1" /></sentence><sentence text="9-156] for Cmax and 146 (90% CI, 126-171) for AUClast Exposure to M-III and M-IV was reduced by 10% to 13%"><entity charOffset="66-77" id="DDI-PubMed.27504016.s17.e0" text="M-III" /><entity charOffset="76-87" id="DDI-PubMed.27504016.s17.e1" text="M-IV" /><pair ddi="false" e1="DDI-PubMed.27504016.s17.e0" e2="DDI-PubMed.27504016.s17.e0" /><pair ddi="false" e1="DDI-PubMed.27504016.s17.e0" e2="DDI-PubMed.27504016.s17.e1" /></sentence><sentence text=" Plasma abiraterone concentrations were consistent with previous studies"><entity charOffset="8-19" id="DDI-PubMed.27504016.s18.e0" text="abiraterone" /></sentence><sentence text=" These results show that abiraterone only weakly inhibits CYP2C8 in vivo"><entity charOffset="25-36" id="DDI-PubMed.27504016.s19.e0" text="abiraterone" /></sentence><sentence text="" /></document>